To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.

NCT00910871 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

241

Enrollment

INDUSTRY

Sponsor class

Conditions

Tuberculosis

Interventions

DRUG: TMC207
DRUG: Background Regimen (BR) for MDR-TB

Sponsor

Janssen Infectious Diseases BVBA